SK bioscience Co.,Ltd. (KRX:302440)

Market Cap	4.10T
Revenue (ttm)	624.03B
Net Income (ttm)	-5.90B
Shares Out	78.37M
EPS (ttm)	-75.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,511
Average Volume	125,766
Open	53,200
Previous Close	53,100
Day's Range	52,300 - 53,400
52-Week Range	35,800 - 61,300
Beta	1.15
RSI	47.56
Earnings Date	Jan 29, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 917
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 302440